Thymalin — thymic peptide bioregulator research
Thymalin is the thymic peptide in the St Petersburg “short peptide bioregulator” family — the immune-system counterpart to the pineal peptide Epitalon. Where Epitalon is studied around telomerase and neuroendocrine rhythm, Thymalin is studied around the thymus: the differentiation of immune-lineage cells, the gene-expression activity of its constituent short peptides, and thymic tissue biology. The mechanistic literature is detailed; the independent human-outcome evidence is thin.
What Thymalin actually is
Thymalin is a peptide preparation obtained from the thymus gland, developed and studied at the St Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues. Within the bioregulator programme it is the thymic member of a set of tissue-specific short peptides; its activity is associated in the literature with short peptides including the dipeptides Lys-Glu (KE) and Glu-Trp (EW). The research framing is “peptide bioregulation” — the hypothesis that short peptides associated with a particular tissue modulate gene expression and cell differentiation in that tissue.
What the mechanism research shows
The peer-reviewed findings cluster into three areas:
- Haematopoietic stem-cell differentiation. A 2020 study by Khavinson and colleagues in Bull Exp Biol Med reported that Thymalin influences the differentiation of human haematopoietic stem cells toward immune-cell lineages in culture [1]. This is the central mechanistic claim — activity at the level of immune-cell development rather than a downstream clinical endpoint.
- Gene-expression activity of the constituent dipeptides. A 2023 study in the International Journal of Molecular Sciences examined how the KE and EW dipeptides associated with the Thymalin preparation affect gene expression and protein synthesis — work that tries to localise the activity to defined short-peptide constituents rather than an undefined extract [2].
- Thymic tissue biology. Older histology work documented the presence and activity of Thymalin in developing thymic and respiratory tissue, consistent with the molecule’s framing as a tissue-specific bioregulator [3].
Honest take: the Thymalin mechanism work is genuinely detailed at the cell-differentiation and gene-expression level. What it is not is a body of independent randomised human trials — the strongest evidence is mechanistic and largely from a single research lineage.
Where it sits in the Khavinson bioregulator family
Thymalin is the thymic (immune) member of the short peptide bioregulator family. The pineal member is Epitalon, and our Khavinson bioregulators overview covers the class and the bioregulation hypothesis as a whole. It is a separate molecule from the thymosins — thymosin beta-4 (researched as TB-500) is discussed in our TB-500 synopsis. For the broader UAE sourcing picture see the research peptides in the UAE overview.
The UAE research-supply landscape
Thymalin is supplied in the UAE as a lyophilised powder, commonly in a 10 mgresearch vial. As a peptide preparation rather than a single defined small molecule, batch-to-batch consistency and documented purity matter especially — the COA and a third-party assay are what separate a credible research-grade supply from an unverified one.
Open questions
What the published literature has not resolved:
- Independent replication. As with the other Khavinson peptides, most of the evidence traces to one research lineage; broad independent replication is limited.
- Composition. Whether the activity is fully accounted for by the defined dipeptides (KE, EW) or involves the wider preparation is still being characterised.
- Human outcomes. The mechanistic and model data are not matched by an independent randomised human-outcome evidence base.
- Pharmacokinetics. Absorption, distribution and metabolism of the constituent peptides in humans are poorly described in the public record.
Thymalin research cluster — deeper dives
Three companion deep-dives go under this overview, each on one axis of the Thymalin record:
- Thymalin mechanism research — the molecular layer: the KE (Lys-Glu) and EW (Glu-Trp) dipeptides, their predicted DNA-sequence binding, cytokine-synthesis modulation in vitro, and the haematopoietic-stem-cell differentiation signal.
- Thymalin immune and clinical research — the evidence graded honestly: the cell-level immune signal, the 266-patient 6–8 year controlled study (described, not promoted), and the single-research-lineage caveat.
- Thymalin dosing research protocols — what the studies administered (no validated human dose), why reconstituting a polypeptide complex differs from a single peptide, storage, and cycles-as-convention.
Further reading
Peer-reviewed citations used inline:
- [1] Khavinson, et al. — Bull Exp Biol Med 2020. “Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.” DOI 10.1007/s10517-020-05016-z.
- [2] Linkova, et al. — Int J Mol Sci 2023. The influence of KE and EW dipeptides in the composition of Thymalin on gene expression and protein synthesis. DOI 10.3390/ijms241713377.
- [3] Khlystova, et al. — Bull Exp Biol Med 2003. Thymalin in developing respiratory organs of the human fetus. DOI 10.1023/a:1025449923475.
Last reviewed 11 June 2026. Wellness Labs supplies Thymalin as research-grade lyophilised powder for non-clinical investigation. Editorial inbox: info@uaewellnesslab.com.
Frequently asked questions
- What is Thymalin?
- Thymalin is a peptide preparation derived from the thymus gland, studied by the St Petersburg Institute of Bioregulation and Gerontology as a thymic bioregulator. In the Khavinson research family it is the immune-system counterpart to the pineal peptide Epitalon. Research describes it as a complex whose activity is associated with short peptides — including the dipeptides Lys-Glu (KE) and Glu-Trp (EW) — that influence the differentiation of immune-lineage cells. It is supplied research-grade as a lyophilised powder for non-clinical investigation, commonly in 10 mg vials.
- What does the mechanism research show?
- A 2020 study by Khavinson and colleagues in Bull Exp Biol Med reported that Thymalin influences the differentiation of human haematopoietic stem cells toward immune-cell lineages in culture. A 2023 study in the International Journal of Molecular Sciences examined how the KE and EW dipeptides associated with the preparation affect gene expression and protein synthesis. The work is mechanistic and largely in-vitro or model-based; it characterises how the peptide signals, not a validated clinical outcome.
- Is Thymalin the same as thymosin or TB-500?
- No. Thymalin is a distinct thymus-derived peptide preparation from the Khavinson bioregulator lineage. Thymosin alpha-1 and thymosin beta-4 (the latter sold research-grade as TB-500) are separate, individually-defined thymic peptides with their own literature. They share a thymic origin and an interest in immune and tissue biology, but they are different molecules with different sequences and different research records.
- How is research-grade Thymalin stored and reconstituted?
- Thymalin is supplied as a lyophilised (freeze-dried) powder, stable for extended periods at -20°C protected from light. For research use it is reconstituted with bacteriostatic water and then held at 2-8°C, typically used within about 28 days. As with any peptide preparation, a third-party purity assay and a batch certificate of analysis are the markers that distinguish a serious research-grade supply from an unverified one.
- Is Thymalin an approved medicine?
- Thymalin has a long history of study and use within the Russian research and clinical system, but it is not approved as a medicine by the FDA, EMA, or equivalent Western regulators, and the independent peer-reviewed human evidence base is limited compared with the mechanistic literature. It is supplied for research use only — not for human consumption — and any clinical-sounding claims should be treated as extrapolations from preclinical and model data.
- Where does Thymalin sit among the Khavinson bioregulators?
- Thymalin is the thymic (immune) member of the short peptide bioregulator family developed by the St Petersburg gerontology group. Epitalon is the pineal member, and there are tissue-specific peptides associated with other organs. The unifying idea in that research programme is "peptide bioregulation" — that short peptides associated with a given tissue influence gene expression and cell differentiation in that tissue. The hypothesis is well-developed in the group’s own literature and less established in independent replication.